A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 715
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SABR
Long Form : stereotactic ablative radiotherapy
No. Year Title Co-occurring Abbreviation
2022 An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone". BED, re-RT
2022 Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy. ---
2022 Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis. ---
2021 3D-printed patient-specific pelvis phantom for dosimetry measurements for prostate stereotactic radiotherapy with dominant intraprostatic lesion boost. CT, FFF
2021 A customizable anthropomorphic phantom for dosimetric verification of 3D-printed lung, tissue, and bone density materials. PLA, VMAT
2021 A feasibility study of hyoscine butylbromide (buscopan) to improve image quality of cone beam computed tomography during abdominal/pelvic Stereotactic Ablative Radiotherapy. CBCT, i.v, IM
2021 A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. FLP, PMD, tPMC
2021 A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. ICIs, mNSCLC, OS, RT, TME
2021 A novel tool for assessing the correlation of internal/external markers during SGRT guided stereotactic ablative radiotherapy treatments. SGRT, SRP
10  2021 A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report. NSCLC, PFS, SBRT, TPS
11  2021 A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. ccRCC, RAPPORT, RECIST 1.1
12  2021 A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. ACCI, ES-NSCLC, HR, OS
13  2021 A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR. CT, FDG-PET, HRF, LR, NSCLC, RILI
14  2021 Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy. ARREST, MTD
15  2021 Acute and Late Esophageal Toxicity Following Stereotactic Ablative Radiotherapy to Thoracic Tumors near or Abutting the Esophagus. CTCAE
16  2021 Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. ADT, CHAARTED, HRA, PFS, PLND, PLNRT, SOC
17  2021 An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. OARs
18  2021 Assessment of the Sun Nuclear ArcCHECK to detect errors in 6MV FFF VMAT delivery of brain SABR using ROC analysis. DLG, MLC, QA, ROC
19  2021 Automatic evaluation of contours in radiotherapy planning utilising conformity indices and machine learning. CIs, OAR, TV
20  2021 Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. CI, DCR, mCRPC, ORR, OS, rPFS
21  2021 Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients. GTV, LRFS, MLD, OS, PFS, PTV, UK
22  2021 Can reducing planning safety margins broaden the inclusion criteria for lung stereotactic ablative body radiotherapy? NSCLC, OAR
23  2021 Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience. VT
24  2021 Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage non-small-cell lung cancer. BH, MR, NSCLC
25  2021 Characteristics Assessment of Online YouTube Videos on Radiotherapy for Lung Cancer. SBRT
26  2021 Comparison of Intrafractional Motion in Head and Neck Cancer Between Two Immobilization Methods During Stereotactic Ablative Radiation Therapy by CyberKnife. PTV
27  2021 Computational ECG mapping and respiratory gating to optimize stereotactic ablative radiotherapy workflow for refractory ventricular tachycardia. ECG, VT
28  2021 Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. CMR, DCR, LCT, NSCLC, OS, PFS, TKI
29  2021 Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease. ICER, QALY, SC, WTP
30  2021 Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. bNED, HT, MDT, PCa, PSMA
31  2021 CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers. ---
32  2021 Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy. MR, PTV
33  2021 Design of a motion simulation system to assist respiratory gating for radiation therapy. EBT3, MUs
34  2021 Detection of second primary lung cancers on surveillance imaging following stereotactic ablative radiotherapy for non-small cell lung cancer. NSCLC, OS, SPLC
35  2021 Development of a Margin Determination Framework for Tumor-Tracking Radiation Therapy With Intraoperatively Implanted Fiducial Markers. FMs, GTV, IIFMs, ITV, ITV
36  2021 Dose calculation and reporting with a linear Boltzman transport equation solver in vertebral SABR. Dm, Dw, LBTE
37  2021 Evidence-Based Planning Target Volume Margin Reduction for Modern Lung Stereotactic Ablative Radiation Therapy Using Deformable Registration. CBCT, FFF, IGTV, PTV
38  2021 Extended application of a CT-based artificial intelligence prognostication model in patients with primary lung cancer undergoing stereotactic ablative radiotherapy. AUC, CI, CT, DFS, HR, LRFS, OS
39  2021 Factors Associated with Radiation Toxicity and Survival in Patients with Presumed Early-Stage Non-Small Cell Lung Cancer Receiving Empiric Stereotactic Ablative Radiotherapy. NSCLC
40  2021 Feasibility study on stereotactic radiotherapy for total pulmonary vein isolation in a canine model. LA, PV
41  2021 Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers. ---
42  2021 Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT. CCRT, HypoRT, LPFS, mLPFS, mOS, mPFS, NSCLC, OS, SIB, VMAT
43  2021 Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy. MR, NTCP, OARs
44  2021 Implementation of Single-Fraction Lung Stereotactic Ablative Radiotherapy in a Multicenter Provincial Cancer Program During the COVID-19 Pandemic. COVID-19, SF
45  2021 Implementation of Stereotactic MRI-Guided Adaptive Radiotherapy (SMART) for Hepatobiliary and Pancreatic Cancers in the United Kingdom - Fifty in Five. HPB, OARs, SMART
46  2021 Intrafraction motion monitoring to determine PTV margins in early stage breast cancer patients receiving neoadjuvant partial breast SABR. A/P, CBCTs, I/S, L/R, PTV
47  2021 Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. ---
48  2021 Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription. IMRT, PTV
49  2021 Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. CRC, LF
50  2021 Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. OM, OS, PFS, TNBC
51  2021 Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases. MR
52  2021 Mature Experiences Using Local Therapy for Oligometastases. ---
53  2021 MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. pPR
54  2021 Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities. CSS, LC, MFS, OS, pCR, RT, STS
55  2021 Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. AUC, NCDB, NSCLC, OS, ROC
56  2021 Non-invasive ablation of arrhythmias with stereotactic ablative radiotherapy. SBRT, STAR, VT
57  2021 Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy. mNSCLC, NSCLC, PFS
58  2021 On the reduction of aperture complexity in kidney SABR. FFF, MU, VMAT
59  2021 Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. AE, HD-IL2, mRCC, ORR, OS, PFS, RCC
60  2021 Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. KBP, OAR, QA
61  2021 Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. CRPC, OS, TTR
62  2021 Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study. CTP, NSCLC, pCR, RPA, SUV
63  2021 PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer. ADT, CI, PSA, PSMA-11-PET
64  2021 Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: A longitudinal study. NSCLC, QoL, VATS
65  2021 Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. LN, NSCLC
66  2021 Radiation and immunotherapy combinations in non-small cell lung cancer. NSCLC
67  2021 Radiotherapy in nodal oligorecurrent prostate cancer. ADT, ENRT
68  2021 Reducing the impact on renal function of kidney SABR through management of respiratory motion. GFR, GTV, ITV, MM, TMA
69  2021 Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases. ---
70  2021 Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. FFLP, LAPC, LC, OS, PFS, RAdAR, SIB
71  2021 Role of Thermal Ablation in Colorectal Cancer Lung Metastases. ESMO, LC, OS
72  2021 SABR in oligometastatic breast cancer: Current status and future directions. OMBC
73  2021 SABR pre-treatment checks using alanine and nanoDot dosimeters. EPR, QA
74  2021 Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices. CIED, Dmax, ICD, PM, RT
75  2021 Shared Decision Making in Early-Stage Non-small Cell Lung Cancer: A Systematic Review. NSCLC
76  2021 Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. AEs, HR
77  2021 Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives. ESMO, NCCN, NSCLC
78  2021 Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible. EQD2, ROC, RT
79  2021 Stereotactic ablative body radiotherapy for ventricular tachycardia: An alternative therapy for refractory patients. ---
80  2021 Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. NHS
81  2021 Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. CI, mPFS, mRCC
82  2021 Stereotactic ablative radiation therapy for spinal metastases: experience at a single Brazilian institution. LC, OS
83  2021 Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis. CI, CSS, DM, DMFS, ES-NSCLC, LR, LRFS, OS, RR, RRFS, SPLC
84  2021 Stereotactic ablative radiotherapy for early stage lung cancer and lung metastases in a New Zealand population. ---
85  2021 Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. CI, HCC, LC, OS
86  2021 Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. HR, NSCLC, VATS L-MLND
87  2021 Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study. LC, PFS, WD-NELM
88  2021 Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis. CI, LC, OS, SCLC
89  2021 Stereotactic ablative radiotherapy versus surgery in older patients with stage I lung cancer. ---
90  2021 Stereotactic Arrhythmia Radioablation as a Novel Treatment Approach for Cardiac Arrhythmias: Facts and Limitations. AF, QA, STAR, VT
91  2021 Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis. OS
92  2021 Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. AEs, ccRCC, DCR, FFLP, ORR, OS, PFS
93  2021 Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring. KIM, LARK
94  2021 Superparamagnetic iron oxide-enhanced MRI-guided stereotactic ablative radiation therapy for liver metastasis. SPIO
95  2021 Survival and morbidity following stereotactic radiotherapy of hepatocellular carcinoma: a ten-year, single institution experience. HCC
96  2021 Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease. ---
97  2021 The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: single center experience. BRFS, GI, GU, PTV, UHRT, VMAT
98  2021 The Impact of Intra-thoracic Anatomical Changes upon the Delivery of Lung Stereotactic Ablative Radiotherapy. CBCT, GTV, ITACs
99  2021 The markerless lung target tracking AAPM Grand Challenge (MATCH) results. kV, MATCH, MATCH, MLTT, MV
100  2021 The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review. CFRT, LC, mRCC, RCC, SBRT, SRS